PRME Prime Medicine, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1894562 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY55.3%
TTM net income YoY-2.7%
TTM EPS YoY18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,498.1%
Net margin-4,342.4%
FCF margin-3,607.4%
EBITDA margin-4,340.0%
Returns
ROE-146.8%
ROA-62.8%
ROIC (approx.)-2,278.6%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets64.7%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-12.1%
Payout ratio—
Capex / revenue97.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.21M | — | — | $838,000 | $1.23M | $1.11M | $1.45M | $2.18M |
| R&D expense | $34.12M | $33.40M | $34.10M | $34.71M | $43.99M | $41.38M | $40.56M | $34.10M |
| SG&A expense | $10.02M | $11.04M | $17.41M | $14.74M | $11.21M | $13.12M | $13.28M | $12.30M |
| Operating income | -$39.93M | -$43.28M | -$50.65M | -$48.61M | -$53.97M | -$53.38M | -$52.39M | -$44.22M |
| Income tax | — | — | — | — | — | $0 | $0 | $0 |
| Net income | -$39.04M | -$42.11M | -$49.12M | -$46.08M | -$50.58M | -$52.59M | -$51.89M | -$42.28M |
| EBITDA | -$38.17M | -$41.50M | -$48.80M | -$46.73M | -$52.09M | -$51.51M | -$50.69M | -$42.51M |
| EPS (basic) | -0.22 | -0.24 | -0.28 | — | -0.32 | -0.41 | -0.40 | — |
| EPS (diluted) | -0.22 | -0.24 | -0.28 | — | -0.32 | -0.41 | -0.40 | — |
| Weighted avg. shares (diluted) | 177.86M | 177.22M | 177.10M | — | 160.50M | 129.19M | 130.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $54.89M | $47.45M | $64.11M | $63.03M | $71.40M | $53.80M | $91.88M | $196.54M |
| Short-term investments | $6.27M | $47.62M | $71.39M | $114.65M | — | — | — | — |
| Current assets | $63.69M | $96.80M | $137.89M | $181.29M | $231.41M | $121.29M | $163.76M | $211.89M |
| PP&E, net | $15.62M | $17.08M | $18.82M | $20.57M | $22.05M | $23.83M | $24.96M | $24.40M |
| Total assets | $213.85M | $249.04M | $294.73M | $342.73M | $385.01M | $279.01M | $328.16M | $297.51M |
| Current liabilities | $35.63M | $31.69M | $36.29M | $37.45M | $35.02M | $34.11M | $34.29M | $37.96M |
| Total liabilities | $205.42M | $209.23M | $218.03M | $221.87M | $223.19M | $218.15M | $221.24M | $144.36M |
| Shareholders' equity | $8.44M | $39.81M | $76.70M | $120.87M | $161.82M | $60.86M | $106.92M | $153.15M |
| Shares outstanding | 181.39M | 180.74M | 180.62M | 180.51M | 180.31M | 134.49M | 131.16M | 131.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$36.68M | -$41.05M | -$42.71M | -$37.26M | -$35.04M | -$41.41M | -$48.86M | $16.25M |
| Capital expenditure | $298,000 | $46,000 | $214,000 | $290,000 | $247,000 | $1.57M | $2.42M | $1.79M |
| Free cash flow | -$36.98M | -$41.09M | -$42.92M | -$37.55M | -$35.29M | -$42.98M | -$51.28M | $14.45M |
| Investing cash flow | $41.25M | $24.03M | $43.39M | $28.33M | -$92.12M | $2.77M | -$47.74M | $48.25M |
| Financing cash flow | $2.87M | $361,000 | $393,000 | $562,000 | $144.75M | $197,000 | $6.00M | $1,000 |
| Depreciation & amortization | $1.76M | $1.78M | $1.86M | $1.88M | $1.88M | $1.86M | $1.70M | $1.72M |
| Stock-based compensation | $4.80M | $4.87M | $4.64M | $4.51M | $12.75M | $6.33M | $5.68M | $5.94M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.